Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells.


Journal

Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055

Informations de publication

Date de publication:
13 11 2020
Historique:
received: 22 11 2019
revised: 20 03 2020
accepted: 30 03 2020
pubmed: 3 4 2020
medline: 27 5 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

Scirrhous-type gastric carcinoma (SGC), which is characterized by the rapid proliferation of cancer cells accompanied by extensive fibrosis, shows extremely poor survival. A reason for the poor prognosis of SGC is that the driver gene responsible for SGC has not been identified. To identify the characteristic driver gene of SGC, we examined the genomic landscape of six human SGC cell lines of OCUM-1, OCUM-2M, OCUM-8, OCUM-9, OCUM-12 and OCUM-14, using multiplex gene panel testing by next-generation sequencing. In this study, the non-synonymous mutations of serine threonine kinase 11/liver kinase B1 (STK11/LKB1) gene were detected in OCUM-12, OCUM-2M and OCUM-14 among the six SGC cell lines. Capillary sequencing analysis confirmed the non-sense or missense mutation of STK11/LKB1 in the three cell lines. Western blot analysis showed that LKB1 expression was decreased in OCUM-12 cells and OCUM-14 cells harboring STK11/LKB1 mutation. The mammalian target of rapamycin (mTOR) inhibitor significantly inhibited the proliferation of OCUM-12 and OCUM-14 cells. The correlations between STK11/LKB1 expression and clinicopathologic features of gastric cancer were examined using 708 primary gastric carcinomas by immunochemical study. The low STK11/LKB1 expression group was significantly associated with SGC, high invasion depth and frequent nodal involvement, in compared with the high STK11/LKB1 expression group. Collectively, our study demonstrated that STK11/LKB1 mutation might be responsible for the progression of SGC, and suggested that mTOR signaling by STK11/LKB1 mutation might be one of therapeutic targets for patients with SGC.

Identifiants

pubmed: 32236518
pii: 5814657
doi: 10.1093/carcin/bgaa031
doi:

Substances chimiques

Biomarkers, Tumor 0
Protein Serine-Threonine Kinases EC 2.7.11.1
STK11 protein, human EC 2.7.11.1
AMP-Activated Protein Kinase Kinases EC 2.7.11.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1616-1623

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Sadaaki Nishimura (S)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Masakazu Yashiro (M)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Tomohiro Sera (T)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Yurie Yamamoto (Y)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Yukako Kushitani (Y)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Atsushi Sugimoto (A)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Shuhei Kushiyama (S)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Shingo Togano (S)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Kenji Kuroda (K)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Tomohisa Okuno (T)

Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan.

Yoshiki Murakami (Y)

Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.

Masaichi Ohira (M)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH